Boehringer Ingelheim

Eureka Therapeutics, Boehringer Ingelheim collaborate on cancer treatments

Friday, May 22, 2015 01:42 PM

California-based Eureka Therapeutics and Germany-based Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology.

More... »

Quest Diagnostics

Icon executives release book for re-engineering clinical trials

Wednesday, April 15, 2015 12:50 PM

Global CRO Icon of Dublin, Ireland, has released the book Re-Engineering Clinical Trials, edited and co-authored by Brendan Buckley, Icon’s chief medical officer, and Peter Schüler, ICON’s senior vice president of global medical and safety services.

More... »


FDA approves record 41 new drugs in 2014, over 40% for rare diseases

Friday, January 16, 2015 02:52 PM

Pharmaceutical innovation had a banner year in 2014, as the FDA approved 41 novel drugs and biologics—the largest number in 18 years and a 52% increase from the 27 approved in 2013.

More... »

Boehringer Ingelheim, WellPoint, HealthCore collaborate

Monday, November 17, 2014 02:34 PM

Boehringer Ingelheim Pharmaceuticals (BIPI); WellPoint, an Indiana-based, U.S. health benefit company; and HealthCore, a Wilmington, Del.-based wholly-owned subsidiary of WellPoint, are launching a research project to identify and address unmet medical needs.

More... »

Cloud Pharmaceuticals ratifies board of directors

Friday, November 7, 2014 01:42 PM

Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has ratified its board of directors. Members of the board include Cloud Pharmaceuticals chairman and CEO Ed Addison, chief scientific officer Shahar Keinan, Ph.D., and chief information officer Lawrence Husick. Other members of the board include:

More... »

Finding Opportunities in the Information Value Chain

Monday, October 27, 2014 07:00 AM

At a recent meeting with a molecular diagnostics client, I went around the room and asked each executive to tell me what business he/she was in.

More... »

Boehringer Ingelheim, CureVac collaborate on lung cancer immunotherapy

Thursday, September 18, 2014 01:39 PM

Boehringer Ingelheim and CureVac, a clinical stage biopharmaceutical company based in Tubingen, Germany, have announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.

More... »

TransCelerate releases recommended approach for protecting personal data in Clinical Study Reports

Wednesday, September 3, 2014 08:20 AM

TransCelerate BioPharma has developed a recommended approach for protecting personal data in Clinical Study Reports (CSRs) shared with researchers, patients and others.

More... »

FDA advisory committee recommends approval of Tiotropium Respimat COPD

Thursday, August 21, 2014 10:31 AM

The FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted (10 yes, three no) that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD patients. If approved by the FDA, the proposed proprietary name for tiotropium bromide inhalation spray will be Spiriva Respimat.

More... »

Peter Hirth joins Trovagene's scientific advisory board

Friday, August 15, 2014 10:34 AM

Trovagene, a California-based developer of cell-free molecular diagnostics, has hired K. Peter Hirth, Ph.D., who joins the company's scientific advisory board. A pioneer in the field of personalized medicine, Hirth led the organizations that developed both Sutent and Zelboraf; two successful targeted cancer therapeutics.

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs